Cathy Cai

Cathy joined JunHe LLP in January 2011, and is working at JunHe Shanghai office as a partner. Cathy worked with A&L Goodbody (a top Irish law firm) as a visiting lawyer from JunHe in the year of 2015. Cathy has also worked with Bristol-Myers Squibb as its senior legal counsel in the year of 2016 under a secondment from JunHe. Cathy is specialized in various M&A transactions and PE investment projects: including (1) cross-border strategic acquisitions; (2) acquisition or sale of equity interests or assets involving foreign invested enterprises in China; (3) outbound investments by Chinese companies; (4) Sino-foreign joint venture projects; (5) investment projects involving investment banks and funds (including various stages from incubation to PreIPO). In the life science sector, Cathy’s representative deals include without limitation: global assets sale of Johnson & Johnson, and its strategic cooperation with AI companies such as TINAVI and Changmugu; acquisition of various Chinese hospitals by Fresenius; joint venture project of AstraZeneca, its management and SDIC Fund Management; and various investment projects involving Lilly Asia Ventures, FountainVest Partners, Oriza Seed, Delos, Alliance Investment and Ally Bridge. In addition, Cathy also advised Bristol-Myers Squibb, Fresenius, ConvaTec, Repligen, Euclid regularly on their general corporate matters, and provided innovative legal solutions to growing companies in the life science industry. Her broad range of transactional experience, her perspective as both PRC and New York lawyer, her knowledge of the Chinese market, and her fluency in English and Mandarin, make Ms. Cai a sought-after advisor in complex M&A and PE investment transactions as well as various commercial initiatives.